Incidence and risk factors for clozapine-induced myocarditis and cardiomyopathy at a regional mental health service in Australia.

Australas Psychiatry

Associate Professor of Rural Psychiatry, Rural Clinical School, University of Queensland, Toowoomba, QLD, and; Medical Director, Adult and Older Persons Mental Health, Gold Coast Health, Gold Coast, QLD, Australia.

Published: April 2016

Objective: To determine the incidence of clozapine-induced myocarditis and cardiomyopathy and identify risk factors.

Method: A cohort of 129 patients initiated on clozapine at Toowoomba Mental Health Service from year 2000 until 2011 was examined to evaluate cases of myocarditis and cardiomyopathy. Risk factors were analysed using multivariable logistic regression.

Results: The incidence of clozapine-induced myocarditis and cardiomyopathy was 3.88% and 4.65% (or 2.26 per 100 patient years), respectively. A significant association was identified between clozapine-induced myocarditis and SSRI use (p = 0.043). Subclinical cardiomyopathy was identified in the absence of symptoms in the majority of cases.

Conclusions: These results illustrate a high incidence of clozapine-induced myocarditis as well as cardiomyopathy, reinforcing the need for a standardised, mandatory monitoring scheme. Concomitant SSRI use as one such potential predictor merits further study.

Download full-text PDF

Source
http://dx.doi.org/10.1177/1039856215604480DOI Listing

Publication Analysis

Top Keywords

clozapine-induced myocarditis
20
myocarditis cardiomyopathy
16
incidence clozapine-induced
12
risk factors
8
mental health
8
health service
8
myocarditis
6
cardiomyopathy
6
clozapine-induced
5
incidence
4

Similar Publications

Introduction And Objectives: Clozapine is the antipsychotic medication with the greatest efficacy in treatment-resistant schizophrenia (TRS). Unfortunately, clozapine is ceased in approximately 0.2% to 8.

View Article and Find Full Text PDF

Relationship Between Clozapine-Induced Inflammation and Eosinophilia: A Retrospective Cohort Study.

Schizophr Bull

December 2024

Department of Psychiatry, Graduate School of Medicine, Tohoku University, Sendai, Miyagi, 980-8574, Japan.

Background And Hypothesis: Eosinophilia has not been highlighted in clozapine-induced adverse inflammatory events, as it is often asymptomatic and self-limiting, while drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome occurs rarely. This study aimed to reveal the temporal relationships between eosinophilia and other inflammatory events during clozapine initiation.

Study Design: The temporal relationships between eosinophilia and other inflammatory events were evaluated among 241 patients with schizophrenia treated with clozapine for the first time at 7 hospitals.

View Article and Find Full Text PDF
Article Synopsis
  • Clozapine use is primarily associated with the risk of neutropenia, but there is limited research on adverse drug reactions (ADRs) and fatal outcomes in patients under 18 years old.
  • A study analyzed 2,825 reports of clozapine usage in this age group, revealing 42 fatal outcomes, with the most common ADR being decreased white blood cell count, while suicide was a significant cause of non-duplicated fatalities.
  • To better prevent fatal outcomes in young patients, child and adolescent psychiatrists should broaden their focus beyond severe neutropenia to include other serious ADRs like pneumonia, while still being cautious of the risk of overdose in those at risk for suicide.
View Article and Find Full Text PDF

Purpose: Clozapine is an antipsychotic which was approved in 1989 for treatment-resistant schizophrenia in the United States (US). There were few randomized trials before its approval and potentially lethal clozapine adverse drug reactions (ADRs), such as agranulocytosis and myocarditis were identified by pharmacovigilance. VigiBase, the WHO global database, is a cornerstone of international pharmacovigilance efforts for ADR identification during post-marketing surveillance.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!